GO:0097128 cyclin D1-CDK4 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097128 (cyclin D1-CDK4 complex) is a cellular_component term describing the heterodimeric protein complex formed by cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4).
• The complex is a serine/threonine kinase module whose activity depends on cyclin D1 binding and on CDK4 phosphorylation of the retinoblastoma protein (RB).
• Cyclin D1-CDK4 assembly and activity are regulated by upstream inputs including calcium/calmodulin-dependent protein kinase I (CaMKI).
• The complex is a central node in oncogenic signaling, linking c-Myc and Ras pathways to cell-cycle progression and contributing to tumor growth, migration and invasion.
• Cyclin D1-CDK4 has non-canonical roles beyond proliferation, including regulation of gluconeogenesis and a dynamic expression pattern in human placenta during gestation.
• The complex is a validated drug target; small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) can degrade or inhibit cyclin D1-CDK4/6.
Description
The cyclin D1-CDK4 complex (GO:0097128) is a cellular_component term that defines the physical and functional association between cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle, and cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner. The cyclin D1-CDK4 complex is therefore a regulatory module that couples extracellular growth signals to the phosphorylation of downstream substrates, most notably the retinoblastoma protein (RB). Because the complex sits at the G1/S transition, its assembly, activity and substrate specificity are of broad interest to cancer biologists, developmental biologists and drug-discovery researchers. Beyond its canonical cell-cycle role, the cyclin D1-CDK4 complex has been implicated in tissue-specific processes such as placental development and systemic metabolic regulation, including gluconeogenesis. The complex also serves as a platform for an oncogenic interactome that can be used to identify potential novel oncogenes and clinical prognostic markers. These findings have expanded the view of GO:0097128 from a simple kinase-cyclin pair to a context-dependent signaling hub. For researchers, GO:0097128 provides a precise annotation target for experiments that perturb complex assembly, catalytic activity or degradation. The complex can be inhibited pharmacologically, degraded by targeted chimeras, or modulated by upstream kinases such as CaMKI. Understanding the composition, regulation and disease relevance of the cyclin D1-CDK4 complex is therefore essential for mechanistic studies and for the development of targeted therapies.
cyclin D1-CDK4 complex At A Glance
| GO ID | GO:0097128 |
|---|---|
| GO term | cyclin D1-CDK4 complex |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Serine/threonine kinase module that phosphorylates downstream substrates such as RB and links growth signals to cell-cycle progression |
| Complex components | Cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4) |
| Regulatory input | Calcium/calmodulin-dependent protein kinase I (CaMKI) regulates cyclin D1/Cdk4 complexes |
| Disease relevance | Implicated in cancer, including melanoma growth, migration and invasion, and in oncogenic signaling networks |
| Therapeutic targeting | Inhibited by small molecules and degraded by PROTACs targeting cyclin D1-CDK4/6 |
What Is GO:0097128?
GO:0097128 describes a protein complex consisting of cyclin D1 and cyclin-dependent kinase 4 (CDK4). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle, and cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner. In practical terms, the term captures the heterodimeric assembly through which cyclin D1 acts as the regulatory subunit and CDK4 as the catalytic subunit, enabling phosphorylation of downstream substrates such as RB.
Why Is cyclin D1-CDK4 complex Important in Cell Biology?
The cyclin D1-CDK4 complex is important because it integrates mitogenic and oncogenic signals with the core cell-cycle machinery. Its assembly and activity are required for phosphorylation of RB and for progression through the G1/S transition, making it a central node in proliferation control. The complex also participates in non-canonical biology, including gluconeogenesis and placental development, and it is a validated target for cancer therapy through both inhibition and targeted degradation. Consequently, GO:0097128 is a key annotation for studies of cell-cycle regulation, oncogenic signaling and drug response.
• Controls G1/S transition by phosphorylating RB and related substrates.
• Serves as a convergence point for c-Myc and Ras oncogenic signaling.
• Is a validated target in melanoma and other cancers, where inhibition suppresses tumor growth, migration and invasion.
• Can be degraded by DNA-templated PROTACs, enabling spatially controlled protein degradation.
• Is regulated by CaMKI, linking calcium signaling to cell-cycle control.
• Has tissue-specific roles, including a defined expression pattern in human placenta during gestation.
• Contributes to systemic metabolism, including regulation of gluconeogenesis.
• Provides an oncogenic interactome for discovery of novel oncogenes and prognostic markers.
• Is relevant to radiotherapy response and autophagy modulation in cancer control.
• Offers a precise GO annotation target for CRISPR-based perturbation studies.
Structure and Composition of cyclin D1-CDK4 complex
Cyclin D1 (CCND1) as the regulatory subunit
In simple terms: Cyclin D1 is the partner protein that switches CDK4 on.
Cyclin D1 is the regulatory subunit of the cyclin D1-CDK4 complex. Its abundance is periodic across the cell cycle, and its binding to CDK4 is required for formation of the active heterodimer. Cyclin D1 also serves as a scaffold for an oncogenic interactome, enabling identification of potential novel oncogenes and clinical prognostic markers.
CDK4 as the catalytic subunit
In simple terms: CDK4 is the enzyme that does the phosphorylation work once cyclin D1 binds.
CDK4 is a cyclin-dependent serine/threonine protein kinase that becomes active upon binding to cyclin D1. The catalytic activity of CDK4 within the complex is directed toward substrates such as RB, and the complex is a target for small-molecule inhibitors and targeted degradation strategies.
Heterodimer assembly
In simple terms: The two proteins must come together to form the functional machine.
The cyclin D1-CDK4 complex is a heterodimer assembled from cyclin D1 and CDK4. Assembly is regulated by upstream signals, including calcium/calmodulin-dependent protein kinase I (CaMKI), which regulates cyclin D1/Cdk4 complexes. The complex can also be disrupted by targeted protein degradation approaches.
Substrate and interaction interface
In simple terms: The complex has surfaces that recognize substrates and partner proteins.
The cyclin D1-CDK4 complex phosphorylates downstream substrates such as RB and participates in a broader oncogenic interactome. Its interaction interface is exploited by inhibitors and degraders that target cyclin D1-CDK4/6. The complex also integrates signals from c-Myc and Ras pathways.
Key Genes Involved in GO:0097128 cyclin D1-CDK4 complex
The following genes and proteins are directly or functionally associated with the cyclin D1-CDK4 complex (GO:0097128) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCND1 | Encodes cyclin D1, the regulatory subunit of the cyclin D1-CDK4 complex | Central to complex assembly and oncogenic interactome studies |
| CDK4 | Encodes the catalytic serine/threonine kinase subunit of the complex | Target for inhibitors and PROTACs |
| CDK6 | Cyclin-dependent kinase 6, a related kinase often co-targeted with CDK4 | Relevant to inhibitor and degrader specificity |
| RB1 | Retinoblastoma protein, a key downstream substrate of the complex | Readout of complex activity in cell-cycle studies |
| MYC | c-Myc oncogene that converges on the cyclin D1-CDK4 complex | Used to study oncogenic collaboration with Ras |
| HRAS | Ras oncogene that collaborates with c-Myc at the cyclin D1-CDK4 complex | Model for oncogenic signaling convergence |
| CAMK1 | Calcium/calmodulin-dependent protein kinase I, regulates cyclin D1/Cdk4 complexes | Links calcium signaling to complex regulation |
| CDKN2A | Encodes p16INK4a, a canonical CDK4 inhibitor (contextual regulator of the complex) | Relevant to complex regulation in cancer models |
| CCND2 | Cyclin D2, a related D-type cyclin (contextual partner of CDK4) | Used in comparative cyclin-CDK studies |
| CCND3 | Cyclin D3, a related D-type cyclin (contextual partner of CDK4) | Used in comparative cyclin-CDK studies |
| CDKN1A | Encodes p21, a CDK inhibitor (contextual regulator) | Relevant to cell-cycle checkpoint studies |
| CDKN1B | Encodes p27, a CDK inhibitor (contextual regulator) | Relevant to cell-cycle checkpoint studies |
| E2F1 | Transcription factor downstream of RB phosphorylation (contextual effector) | Readout of complex activity |
| TP53 | Tumor suppressor frequently co-altered in cancers with cyclin D1-CDK4 dysregulation (contextual) | Relevant to cancer model design |
| AKT1 | Kinase in growth-factor signaling upstream of cyclin D1 (contextual) | Relevant to upstream regulation studies |
| MTOR | Growth-signaling kinase upstream of cyclin D1 translation (contextual) | Relevant to regulation of complex abundance |
| BECN1 | Autophagy-related gene implicated in responses to CDK4/6-cyclin D1 inhibition | Relevant to autophagy and radiotherapy studies |
| MAPK1 | Mitogen-activated protein kinase in Ras signaling upstream of cyclin D1 (contextual) | Relevant to oncogenic signaling studies |
How Is cyclin D1-CDK4 complex Regulated?
The cyclin D1-CDK4 complex is regulated at multiple levels. Upstream signaling through c-Myc and Ras converges on the complex, linking oncogenic pathways to its assembly and activity. Calcium/calmodulin-dependent protein kinase I (CaMKI) regulates cyclin D1/Cdk4 complexes, providing a calcium-sensitive input. The complex is also subject to pharmacological inhibition and targeted degradation, indicating that its stability and availability can be experimentally controlled. In addition, the complex participates in autophagy-related responses relevant to radiotherapy, suggesting that its regulation intersects with stress-response pathways.
cyclin D1-CDK4 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCND1 | Metastatic melanoma growth, migration and invasion | Melanoma cell lines with CCND1 knockout or overexpression |
| CDK4 | Cancer cell proliferation and radiotherapy response | CDK4 knockout or point-mutation cell models |
| CDK6 | Cyclin D1-CDK4/6 complex degradation | Knock-in of degron-tagged CDK6 for PROTAC studies |
| MYC | Oncogenic collaboration with Ras at the cyclin D1-CDK4 complex | Isogenic cells with MYC and HRAS perturbations |
| CAMK1 | Regulation of cyclin D1/Cdk4 complexes | CAMK1 knockout or kinase-dead knock-in models |
Cancer and oncogenic signaling
The cyclin D1-CDK4 complex is a central node in oncogenic signaling, where c-Myc and Ras pathways converge to drive proliferation. Its oncogenic interactome has been used to identify potential novel oncogenes and clinical prognostic markers. In metastatic melanoma, inhibition of cyclin D1/CDK4 suppresses tumor growth, migration and invasion. The complex is also relevant to radiotherapy response and autophagy modulation in cancer control.
Metabolic and tissue-specific biology
Beyond cancer, the cyclin D1-CDK4 complex has a role in gluconeogenesis, expanding its function beyond cell-cycle control. In human placenta, the complex shows a defined pattern of expression during gestation, indicating tissue-specific regulation. These findings suggest that GO:0097128 is relevant to developmental and metabolic research in addition to oncology.
Therapeutic targeting and degradation
The complex is a validated drug target. Small-molecule inhibitors of cyclin D1/CDK4 suppress melanoma tumor growth, migration and invasion. DNA-templated, spatially controlled proteolysis-targeting chimeras (PROTACs) can degrade the cyclin D1-CDK4/6 complex proteins, offering a complementary strategy to inhibition. These approaches highlight the translational importance of GO:0097128.
From cyclin D1-CDK4 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CDK4 abolish cyclin D1-CDK4 complex activity? | CDK4 knockout cell line |
| Does a specific CDK4 residue control substrate phosphorylation? | CDK4 point-mutation knock-in |
| Can the complex be degraded in a spatially controlled manner? | Knock-in of degron-tagged CDK4 or CCND1 for PROTAC studies |
| Where and when is the complex assembled in cells? | Tagged knock-in of CCND1 or CDK4 for imaging |
| Does cyclin D1 overexpression drive migration and invasion? | CCND1 overexpression in melanoma cells |
| Does CaMKI regulate complex abundance? | CAMK1 knockout or overexpression models |
How to Study the cyclin D1-CDK4 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between cyclin D1 and CDK4 | Complex assembly studies |
| Kinase activity assay | Phosphorylation of substrates such as RB | Inhibitor testing |
| Immunoblotting | Protein abundance of cyclin D1 and CDK4 | Expression analysis |
| Immunohistochemistry | Tissue expression pattern of the complex | Placental and tumor tissue studies |
| Mass spectrometry interactome | Partner proteins of the complex | Oncogene discovery |
| PROTAC degradation assay | Loss of cyclin D1-CDK4/6 proteins | Targeted degradation studies |
| Migration and invasion assay | Functional effects of complex inhibition | Melanoma metastasis studies |
| Autophagy flux assay | Autophagy modulation after CDK4/6-cyclin D1 inhibition | Radiotherapy response studies |
Co-immunoprecipitation and interactome mapping
Because GO:0097128 is defined by a physical interaction between cyclin D1 and CDK4, co-immunoprecipitation and interactome mapping are core methods. The cyclin D1-CDK4 oncogenic interactome has been used to identify potential novel oncogenes and clinical prognostic markers. These approaches can be combined with mass spectrometry to define complex composition and partner proteins.
Kinase activity assays
The catalytic function of the complex can be measured by kinase activity assays using substrates such as RB. Such assays are useful for testing inhibitors of cyclin D1/CDK4 and for evaluating the impact of upstream regulators such as CaMKI.
Expression and localization analysis
Expression and localization of cyclin D1 and CDK4 can be assessed by immunohistochemistry, immunoblotting and imaging. The pattern of expression of the cyclin D1/CDK4 complex has been characterized in human placenta during gestation, and expression changes are relevant to cancer models.
Targeted degradation and inhibitor assays
Pharmacological inhibition and targeted degradation are key functional assays for the complex. Small-molecule inhibitors of cyclin D1/CDK4 suppress melanoma growth, migration and invasion, while DNA-templated PROTACs degrade cyclin D1-CDK4/6 proteins. These methods allow researchers to test the consequences of complex loss.
How CRISPR Can Be Used to Study GO:0097128 cyclin D1-CDK4 complex
Knockout
CRISPR knockout of CDK4 or CCND1 can abolish formation of the cyclin D1-CDK4 complex, enabling loss-of-function studies of GO:0097128. Such models are useful for testing whether complex activity is required for proliferation, migration and invasion.
Point Mutation
Point-mutation knock-in can be used to dissect catalytic residues or regulatory phosphorylation sites within CDK4 or cyclin D1. These models help determine which molecular features of the complex are required for substrate phosphorylation and downstream signaling.
Knock-in
Knock-in of tags or degrons into CCND1 or CDK4 allows visualization and controlled degradation of the complex. Tagged knock-in models support imaging of complex localization and PROTAC-mediated degradation studies.
Overexpression
Overexpression of cyclin D1 or CDK4 can drive complex formation and oncogenic phenotypes, including increased migration and invasion in melanoma cells. Overexpression models are also useful for studying the oncogenic interactome and its prognostic implications.
How EDITGENE Supports cyclin D1-CDK4 complex Research
Researchers studying cyclin D1-CDK4 complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, catalytic activity or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise perturbation of CCND1, CDK4 and related genes in relevant cellular backgrounds.
Contact EDITGENE today to design your custom CRISPR model for cyclin D1-CDK4 complex research.
Frequently Asked Questions About cyclin D1-CDK4 complex
What is the cyclin D1-CDK4 complex?
The cyclin D1-CDK4 complex (GO:0097128) is a protein complex consisting of cyclin D1 and cyclin-dependent kinase 4 (CDK4), which functions as a serine/threonine kinase module.
What genes are involved in the cyclin D1-CDK4 complex?
The core genes are CCND1 (cyclin D1) and CDK4, with related genes including CDK6, RB1, MYC, HRAS and CAMK1.
What is the function of GO:0097128?
GO:0097128 describes the cyclin D1-CDK4 complex, which phosphorylates downstream substrates such as RB and links growth signals to cell-cycle progression.
How is the cyclin D1-CDK4 complex regulated?
It is regulated by upstream signaling including c-Myc and Ras pathways and by calcium/calmodulin-dependent protein kinase I (CaMKI).
Is the cyclin D1-CDK4 complex a drug target?
Yes, it is a validated target; small-molecule inhibitors and PROTACs can inhibit or degrade cyclin D1-CDK4/6.
What diseases are associated with the cyclin D1-CDK4 complex?
It is associated with cancer, including metastatic melanoma, and has roles in metabolic and placental biology.
How can I study the cyclin D1-CDK4 complex in the lab?
Common methods include co-immunoprecipitation, kinase activity assays, expression analysis, and targeted degradation assays.
What is the role of cyclin D1 in the complex?
Cyclin D1 is the regulatory subunit that binds CDK4 and is required for formation of the active heterodimer.
What is the role of CDK4 in the complex?
CDK4 is the catalytic serine/threonine kinase subunit that becomes active upon binding to cyclin D1.
Can CRISPR be used to study GO:0097128?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models can be used to perturb CCND1 and CDK4 and study complex function.
Conclusion
The cyclin D1-CDK4 complex (GO:0097128) is a central cellular_component that connects growth and oncogenic signaling to cell-cycle progression through the catalytic activity of CDK4 and the regulatory function of cyclin D1. Its roles extend beyond proliferation to metabolism and tissue-specific biology, and it is a validated target for inhibition and targeted degradation. Researchers can interrogate the complex using co-immunoprecipitation, kinase assays, expression analysis and CRISPR-based perturbation. As a precise GO annotation, GO:0097128 supports mechanistic and translational studies of cancer, metabolism and development. EDITGENE provides the CRISPR cell models and bioinformatics needed to test causal roles of complex components in these contexts.
References
- 1. Nardone V et al.. 2021. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.. Int J Mol Sci 22(16) PMID: 34445095
- 2. Hosooka T et al.. 2016. A novel role for the cell cycle regulatory complex cyclin D1-CDK4 in gluconeogenesis.. J Diabetes Investig 7(1):27-8 PMID: 26816597
- 3. De Falco M et al.. 2004. Pattern of expression of cyclin D1/CDK4 complex in human placenta during gestation.. Cell Tissue Res 317(2):187-94 PMID: 15221443
- 4. Kim D et al.. 2025. Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells.. Cancer Cell Int 25(1):42 PMID: 39948552
- 5. Kahl CR et al.. 2004. Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I.. J Biol Chem 279(15):15411-9 PMID: 14754892
- 6. Jirawatnotai S et al.. 2014. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis.. Cell Cycle 13(18):2889-900 PMID: 25486477
- 7. Wang C et al.. 2011. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.. Cell Cycle 10(1):57-67 PMID: 21200143
- 8. Zheng R et al.. 2025. DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1-CDK4/6 Complex Protein Degradation.. J Am Chem Soc 147(33):29742-29755 PMID: 40619689
